The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Molecular Mechanisms of Dyskinesia in Parkinson's Disease, 2003The Role of Abnormal Gap Junction Communication in the Generation of Levodopa-induced Dyskinesia in Parkinson's Disease
We hypothesize that enhanced gap junction communication (GJC) plays an unheralded and important role in the neural mechanisms underlying levodopa-induced dyskinesia (LID). Gap junctions are a special...
-
Molecular Mechanisms of Dyskinesia in Parkinson's Disease, 2003A Trial of Low Frequency Repetitive Transcranial Magnetic Stimulation for Treatment of Dyskinesia
Levodopa-induced dyskinesia (LID) is a major source of disability of many patients with Parkinson's disease (PD). LID may be associated with increased activity of the part of the brain that mediates...
-
Molecular Mechanisms of Dyskinesia in Parkinson's Disease, 2003Anatomical and neurochemical characterization of basal ganglia neuropeptides in levodopainduceddyskinesia
The most common treatment for Parkinson's disease is levodopa (L-DOPA). This usually gives good relief of symptom for many years but, eventually, complications such as abnormal involuntary movements...
-
Molecular Mechanisms of Dyskinesia in Parkinson's Disease, 2003Reversal of Dyskinesias By in-vivo Gene Transfer of L-DOPA Using Adeno-associated Viral Vectors
Parkinson's disease is a result of an extensive loss of the pigmented neurons located in the brain stem (termed the Substantia Nigra). These nerve cells are the principal neurons producing dopamine in...
-
Community Fast Track, 2003Methionine Sulfoxide Reductase A CMRSA and Parkinson’s Disease Pathogenesis
There is a large body of evidence that both defective energy metabolism as well as oxidative damage, which is a consequence of increased production of free radicals, may play a critical role in...
-
Community Fast Track, 2003Multi-single Unit Electrophysiological Characterization of Dyskinesia Induced by Dopamimetic Drugs
Parkinsonian patients develop debilitating motor complications caused by the best treatments of the disease, the levodopa and the dopamine agonists. Among other phenomena, it is known that these...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.